Cost-Effectiveness of Endovascular Thrombectomy in Childhood Stroke: An Analysis of the Save ChildS Study.

"Disclosure: Jens Fiehler reported serving as a paid consultant for Acandis, Boehringer Ingelheim, Cerenovus, Covidien, Evasc Neurovascular, MD Clinicals, Medtronic, Medina, Microvention, Penumbra, Route92, Stryker, and Transverse Medical. Jens Fiehler is also CEO of Eppdata. Dr Chapot reported receiving personal fees from Microvention, Stryker, Medtronic, Balt, Siemens, and Rapid Medical outside the submitted work. Franziska Dorn received personal fees for consultancy from Acandis, Phenox, Balt, and Cerenovus. Hans Henkes reported receiving personal fees and nonfinancial support from Phenox GmbH during the conduct of the study; in addition, Hans Henkes had patents issued to 10 2004 040 868.8, 200580033578.6, 11/ 678,285, 50 2006 012 111.5, PCT/EP 2005/ 009057, 05 777 177.6-2318, and 10 2005 059 670.3, and is coinventor of several other patents related to thrombectomy. Martin Wiesmann reported receiving grants, personal fees, and nonfinancial support from Stryker Neurovascular; personal fees and nonfinancial support from Medtronic, Penumbra Inc, and Siemens Healthcare; and nonfinancial support from ab medica, Acandis, Asahi Intecc, Cerenovus, Kaneka Pharmaceuticals, Mentice AB, Microvention, and Phenox outside the submitted work. Markus Möhlenbruch reported receiving grants and nonfinancial support from Balt; personal fees from Medtronic; grants, personal fees, and nonfinancial support from MicroVention; and grants and personal fees from Stryker outside the submitted work. Alexander Radbruch reported receiving grants and personal fees from Guerbet and Bayer outside the submitted work. André Kemmling reported receiving personal fees from Penumbra, Stryker, and Phenox outside the submitted work. No industry support of the project was obtained."